Gilead Sciences, Inc. $GILD Stock: USS Investment Management Ltd Trims Stake

USS Investment Management Ltd trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.7% during the third quarter, HoldingsChannel reports. The fund owned 222,215 shares of the biopharmaceutical company’s stock after selling 3,736 shares during the quarter. USS Investment Management Ltd’s holdings in Gilead Sciences were worth $33,120,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in GILD. Composition Wealth LLC boosted its holdings in shares of Gilead Sciences by 7.5% in the 3rd quarter. Composition Wealth LLC now owns 48,831 shares of the biopharmaceutical company’s stock valued at $7,278,000 after buying an additional 3,401 shares during the period. Bank of Nova Scotia acquired a new stake in Gilead Sciences during the second quarter worth about $100,056,000. OMERS ADMINISTRATION Corp acquired a new stake in Gilead Sciences during the second quarter worth about $55,754,000. Groupe la Francaise lifted its holdings in Gilead Sciences by 30.9% in the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after acquiring an additional 11,712 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its holdings in Gilead Sciences by 3.6% in the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after acquiring an additional 10,206 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the completion of the transaction, the insider directly owned 110,684 shares in the company, valued at approximately $18,877,156.20. The trade was a 20.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 237,709 shares of company stock valued at $39,799,137. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on GILD shares. BMO Capital Markets restated an “outperform” rating and issued a $184.00 target price on shares of Gilead Sciences in a research note on Friday, October 30th. Scotiabank increased their price target on Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 30th. Morgan Stanley raised their price target on Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. TD Cowen set a $175.00 price objective on Gilead Sciences in a research report on Wednesday. Finally, Needham & Company LLC set a $175.00 price objective on Gilead Sciences in a research report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $171.63.

Read Our Latest Analysis on GILD

Gilead Sciences Stock Down 1.4%

GILD stock opened at $166.53 on Friday. The stock has a market cap of $206.55 billion, a PE ratio of -52.70 and a beta of 0.35. The firm’s 50-day simple moving average is $156.80 and its 200 day simple moving average is $142.34. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same period in the previous year, the business posted $2.47 EPS. Gilead Sciences’s revenue was up 6.8% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s payout ratio is -103.80%.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.